

Umberto Vitolo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1327610/publications.pdf>

Version: 2024-02-01

193
papers

12,698
citations

34076

52
h-index

25770

108
g-index

194
all docs

194
docs citations

194
times ranked

8987
citing authors

#	ARTICLE	IF	CITATIONS
1	Follicular Lymphoma International Prognostic Index. <i>Blood</i> , 2004, 104, 1258-1265.	0.6	1,552
2	Early Interim 2-[¹⁸ F]Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography Is Prognostically Superior to International Prognostic Score in Advanced-Stage Hodgkin's Lymphoma: A Report From a Joint Italian-Danish Study. <i>Journal of Clinical Oncology</i> , 2007, 25, 3746-3752.	0.8	799
3	Follicular Lymphoma International Prognostic Index 2: A New Prognostic Index for Follicular Lymphoma Developed by the International Follicular Lymphoma Prognostic Factor Project. <i>Journal of Clinical Oncology</i> , 2009, 27, 4555-4562.	0.8	613
4	Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. <i>Blood</i> , 2004, 103, 2474-2479.	0.6	549
5	Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. <i>Lancet, The</i> , 2019, 393, 229-240.	6.3	517
6	Phase III Trial of Consolidation Therapy With Yttrium-90â€“Ibritumomab Tiuxetan Compared With No Additional Therapy After First Remission in Advanced Follicular Lymphoma. <i>Journal of Clinical Oncology</i> , 2008, 26, 5156-5164.	0.8	431
7	ABVD versus BEACOPP for Hodgkin's Lymphoma When High-Dose Salvage Is Planned. <i>New England Journal of Medicine</i> , 2011, 365, 203-212.	13.9	379
8	Obinutuzumab or Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2017, 35, 3529-3537.	0.8	333
9	Prospective, multicenter randomized GITMO/III trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage. <i>Blood</i> , 2008, 111, 4004-4013.	0.6	243
10	R-CVP Versus R-CHOP Versus R-FM for the Initial Treatment of Patients With Advanced-Stage Follicular Lymphoma: Results of the FOLLO5 Trial Conducted by the Fondazione Italiana Linfomi. <i>Journal of Clinical Oncology</i> , 2013, 31, 1506-1513.	0.8	223
11	Interim 18-FDG-PET/CT failed to predict the outcome in diffuse large B-cell lymphoma patients treated at the diagnosis with rituximab-CHOP. <i>Blood</i> , 2012, 119, 2066-2073.	0.6	217
12	The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin's disease. <i>Haematologica</i> , 2006, 91, 475-81.	1.7	213
13	Addition of Rituximab to Chlorambucil Produces Superior Event-Free Survival in the Treatment of Patients With Extranodal Marginal-Zone B-Cell Lymphoma: 5-Year Analysis of the IELSG-19 Randomized Study. <i>Journal of Clinical Oncology</i> , 2013, 31, 565-572.	0.8	198
14	ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL). <i>Annals of Oncology</i> , 2013, 24, 561-576.	0.6	193
15	First-Line Treatment for Primary Testicular Diffuse Large B-Cell Lymphoma With Rituximab-CHOP, CNS Prophylaxis, and Contralateral Testis Irradiation: Final Results of an International Phase II Trial. <i>Journal of Clinical Oncology</i> , 2011, 29, 2766-2772.	0.8	190
16	ABVD Versus Modified Stanford V Versus MOPPEBVCAD With Optional and Limited Radiotherapy in Intermediate- and Advanced-Stage Hodgkin's Lymphoma: Final Results of a Multicenter Randomized Trial by the Intergruppo Italiano Linfomi. <i>Journal of Clinical Oncology</i> , 2005, 23, 9198-9207.	0.8	167
17	Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial. <i>Lancet Oncology, The</i> , 2014, 15, 730-737.	5.1	164
18	Early CPAP prevents evolution of acute lung injury in patients with hematologic malignancy. <i>Intensive Care Medicine</i> , 2010, 36, 1666-1674.	3.9	152

#	ARTICLE	IF	CITATIONS
19	[¹⁸ F]Fluorodeoxyglucose Positron Emission Tomography Predicts Survival After Chemoimmunotherapy for Primary Mediastinal Large B-Cell Lymphoma: Results of the International Extranodal Lymphoma Study Group IELSG-26 Study. <i>Journal of Clinical Oncology</i> , 2014, 32, 1769-1775.	0.8	149
20	Final Results of the IELSG-19 Randomized Trial of Mucosa-Associated Lymphoid Tissue Lymphoma: Improved Event-Free and Progression-Free Survival With Rituximab Plus Chlorambucil Versus Either Chlorambucil or Rituximab Monotherapy. <i>Journal of Clinical Oncology</i> , 2017, 35, 1905-1912.	0.8	143
21	ROBUST: A Phase III Study of Lenalidomide Plus R-CHOP Versus Placebo Plus R-CHOP in Previously Untreated Patients With ABC-Type Diffuse Large B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 1317-1328.	0.8	132
22	Interim Positron Emission Tomography Response—Adapted Therapy in Advanced-Stage Hodgkin Lymphoma: Final Results of the Phase II Part of the HD0801 Study. <i>Journal of Clinical Oncology</i> , 2016, 34, 1376-1385.	0.8	128
23	Obinutuzumab (GA101) plus CHOP or FC in relapsed/refractory follicular lymphoma: results of the GAUDI study (BO21000). <i>Blood</i> , 2013, 122, 1137-1143.	0.6	120
24	Minimal Residual Disease Detection by Droplet Digital PCR in Multiple Myeloma, Mantle Cell Lymphoma, and Follicular Lymphoma. <i>Journal of Molecular Diagnostics</i> , 2015, 17, 652-660.	1.2	115
25	Long-Term Results of the FOLL05 Trial Comparing R-CVP Versus R-CHOP Versus R-FM for the Initial Treatment of Patients With Advanced-Stage Symptomatic Follicular Lymphoma. <i>Journal of Clinical Oncology</i> , 2018, 36, 689-696.	0.8	107
26	Primary testicular lymphoma. <i>Critical Reviews in Oncology/Hematology</i> , 2008, 65, 183-189.	2.0	106
27	Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi. <i>Lancet Haematology</i> , 2017, 4, e15-e23.	2.2	106
28	Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study. <i>Lancet Oncology</i> , 2017, 18, 1076-1088.	5.1	100
29	Positron emission tomography in the staging of patients with Hodgkin's lymphoma. A prospective multicentric study by the Intergruppo Italiano Linfomi. <i>Annals of Hematology</i> , 2007, 86, 897-903.	0.8	98
30	Minimal Residual Disease after Conventional Treatment Significantly Impacts on Progression-Free Survival of Patients with Follicular Lymphoma: The FIL FOLL05 Trial. <i>Clinical Cancer Research</i> , 2014, 20, 6398-6405.	3.2	94
31	Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study. <i>Lancet Oncology</i> , 2018, 19, 1449-1458.	5.1	93
32	High rate of clinical and molecular remissions in follicular lymphoma patients receiving high-dose sequential chemotherapy and autografting at diagnosis: a multicenter, prospective study by the Gruppo Italiano Trapianto Midollo Osseo (GITMO). <i>Blood</i> , 2002, 100, 1559-1565.	0.6	89
33	Integration of cell of origin into the clinical CNS International Prognostic Index improves CNS relapse prediction in DLBCL. <i>Blood</i> , 2019, 133, 919-926.	0.6	89
34	Thirty-Month Complete Response as a Surrogate End Point in First-Line Follicular Lymphoma Therapy: An Individual Patient-Level Analysis of Multiple Randomized Trials. <i>Journal of Clinical Oncology</i> , 2017, 35, 552-560.	0.8	87
35	Final results of a multicenter trial addressing role of CSF flow cytometric analysis in NHL patients at high risk for CNS dissemination. <i>Blood</i> , 2012, 120, 3222-3228.	0.6	85
36	ROBUST: Lenalidomide-R-CHOP versus placebo-R-CHOP in previously untreated ABC-type diffuse large B-cell lymphoma. <i>Future Oncology</i> , 2016, 12, 1553-1563.	1.1	85

#	ARTICLE	IF	CITATIONS
37	Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program. <i>Blood</i> , 2013, 122, 3759-3766.	0.6	82
38	A randomized, open-label, Phase III study of obinutuzumab or rituximab plus CHOP in patients with previously untreated diffuse large B-Cell lymphoma: final analysis of GOYA. <i>Journal of Hematology and Oncology</i> , 2020, 13, 71.	6.9	82
39	Ibrutinib as Treatment for Patients With Relapsed/Refractory Follicular Lymphoma: Results From the Open-Label, Multicenter, Phase II DAWN Study. <i>Journal of Clinical Oncology</i> , 2018, 36, 2405-2412.	0.8	81
40	High-dose chemotherapy with autologous stem cell support in first-line treatment of aggressive non-Hodgkin lymphoma – Results of a comprehensive meta-analysis. <i>Cancer Treatment Reviews</i> , 2007, 33, 338-346.	3.4	80
41	Lymphoplasmacytic lymphoma – Waldenstrom's macroglobulinemia. <i>Critical Reviews in Oncology/Hematology</i> , 2008, 67, 172-185.	2.0	75
42	Phase III Intergroup Study of Fludarabine Phosphate Compared With Cyclophosphamide, Vincristine, and Prednisone Chemotherapy in Newly Diagnosed Patients With Stage III and IV Low-Grade Malignant Non-Hodgkin's Lymphoma. <i>Journal of Clinical Oncology</i> , 2006, 24, 1590-1596.	0.8	73
43	RD – CODOX – IVAC with rituximab and intrathecal liposomal cytarabine in adult Burkitt lymphoma and – unclassifiable – highly aggressive B – cell lymphoma. <i>British Journal of Haematology</i> , 2012, 156, 234-244.	1.2	72
44	High-dose sequential chemotherapy and peripheral blood progenitor cell autografting in patients with refractory and/or recurrent Hodgkin lymphoma. <i>Cancer</i> , 2003, 97, 2748-2759.	2.0	71
45	Practice guidelines for the management of extranodal non-Hodgkin's lymphomas of adult non-immunodeficient patients. Part I: primary lung and mediastinal lymphomas. A project of the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. <i>Haematologica</i> , 2008, 93, 1364-1371.	1.7	66
46	Dose-dense and high-dose chemotherapy plus rituximab with autologous stem cell transplantation for primary treatment of diffuse large B-cell lymphoma with a poor prognosis: a phase II multicenter study. <i>Haematologica</i> , 2009, 94, 1250-1258.	1.7	65
47	Brentuximab vedotin in relapsed/refractory Hodgkin's lymphoma: the Italian experience and results of its use in daily clinical practice outside clinical trials. <i>Haematologica</i> , 2013, 98, 1232-1236.	1.7	65
48	The combined role of biomarkers and interim PET scan in prediction of treatment outcome in classical Hodgkin's lymphoma: a retrospective, European, multicentre cohort study. <i>Lancet Haematology</i> , 2016, 3, e467-e479.	2.2	63
49	Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis. <i>Oncotarget</i> , 2017, 8, 79073-79086.	0.8	63
50	Risk factors for infections in myelofibrosis: role of disease status and treatment. A multicenter study of 507 patients. <i>American Journal of Hematology</i> , 2017, 92, 37-41.	2.0	62
51	Salvage treatment with lenalidomide and dexamethasone in relapsed/refractory mantle cell lymphoma: clinical results and effects on microenvironment and neo-angiogenic biomarkers. <i>Haematologica</i> , 2012, 97, 416-422.	1.7	61
52	Chlorambucil versus observation after anti- <i>Helicobacter</i> therapy in gastric MALT lymphomas: results of the international randomised LY03 trial. <i>British Journal of Haematology</i> , 2009, 144, 367-375.	1.2	60
53	Outcomes in first relapsed-refractory younger patients with mantle cell lymphoma: results from the MANTLE-FIRST study. <i>Leukemia</i> , 2021, 35, 787-795.	3.3	56
54	Validation of POD24 as a robust early clinical end point of poor survival in FL from 5225 patients on 13 clinical trials. <i>Blood</i> , 2022, 139, 1684-1693.	0.6	56

#	ARTICLE	IF	CITATIONS
55	Bendamustine and rituximab combination is safe and effective as salvage regimen in Waldenström macroglobulinemia. <i>Leukemia and Lymphoma</i> , 2015, 56, 2637-2642.	0.6	55
56	Practical management of ibrutinib in the real life: Focus on atrial fibrillation and bleeding. <i>Hematological Oncology</i> , 2018, 36, 624-632.	0.8	55
57	Rituximab Maintenance Compared With Observation After Brief First-Line R-FND Chemoimmunotherapy With Rituximab Consolidation in Patients Age Older Than 60 Years With Advanced Follicular Lymphoma: A Phase III Randomized Study by the Fondazione Italiana Linfomi. <i>Journal of Clinical Oncology</i> , 2013, 31, 3351-3359.	0.8	54
58	Lenalidomide plus cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab is safe and effective in untreated, elderly patients with diffuse large B-cell lymphoma: a phase I study by the Fondazione Italiana Linfomi. <i>Haematologica</i> , 2013, 98, 1732-1738.	1.7	54
59	Outcomes and Prognostic Factors in Angioimmunoblastic T cell Lymphoma: Final Report from the International TCell Project. <i>Blood</i> , 2021, 138, 213-220.	0.6	53
60	Rituximab maintenance improves overall survival of patients with follicular lymphoma—Individual patient data meta-analysis. <i>European Journal of Cancer</i> , 2017, 76, 216-225.	1.3	50
61	The prognostic value of positron emission tomography performed after two courses (<sc>INTERIM-PET</sc>) of standard therapy on treatment outcome in early stage <sc>H</sc>odgkin lymphoma: A multicentric study by the fondazione italiana linfomi (FIL). <i>American Journal of Hematology</i> , 2015, 90, 499-503.	2.0	49
62	Prognostic Impact of Natural Killer Cell Count in Follicular Lymphoma and Diffuse Large B-cell Lymphoma Patients Treated with Immunochemotherapy. <i>Clinical Cancer Research</i> , 2019, 25, 4634-4643.	3.2	49
63	Time to progression of mantle cell lymphoma after high-dose cytarabine-based regimens defines patients risk for death. <i>British Journal of Haematology</i> , 2019, 185, 940-944.	1.2	49
64	Genetic and phenotypic attributes of splenic marginal zone lymphoma. <i>Blood</i> , 2022, 139, 732-747.	0.6	49
65	Long-Term Follow-Up Analysis of HD9601 Trial Comparing ABVD Versus Stanford V Versus MOPP/EBV/CAD in Patients With Newly Diagnosed Advanced-Stage Hodgkin's Lymphoma: A Study From the Intergruppo Italiano Linfomi. <i>Journal of Clinical Oncology</i> , 2011, 29, 4227-4233.	0.8	47
66	Involved-Site Image-Guided Intensity Modulated Versus 3D Conformal Radiation Therapy in Early Stage Supradiaphragmatic Hodgkin Lymphoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 89, 370-375.	0.4	46
67	Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: A multicenter study on 446 patients. <i>Hematological Oncology</i> , 2018, 36, 561-569.	0.8	46
68	Follicular lymphomas. <i>Critical Reviews in Oncology/Hematology</i> , 2008, 66, 248-261.	2.0	44
69	A phase 2 trial of fludarabine and mitoxantrone chemotherapy followed by yttrium-90 ibritumomab tiuxetan for patients with previously untreated, indolent, nonfollicular, non-Hodgkin lymphoma. <i>Cancer</i> , 2008, 112, 856-862.	2.0	43
70	Interim positron emission tomography and clinical outcome in patients with early stage Hodgkin lymphoma treated with combined modality therapy. <i>Leukemia and Lymphoma</i> , 2013, 54, 1183-1187.	0.6	41
71	Clinical relevance of immunophenotype in a retrospective comparative study of 297 peripheral T-cell lymphomas, unspecified, and 496 diffuse large B-cell lymphomas. <i>Cancer</i> , 2004, 101, 1601-1608.	2.0	40
72	Clinical activity of everolimus in relapsed/refractory marginal zone <sc>B</sc>-cell lymphomas: results of a phase <sc>II</sc> study of the <sc>International</sc> <sc>Extranodal</sc> <sc>Lymphoma</sc> <sc>Study</sc> <sc>Group</sc>. <i>British Journal of Haematology</i> , 2014, 166, 69-76.	1.2	39

#	ARTICLE	IF	CITATIONS
73	Update on the molecular pathogenesis and clinical treatment of mantle cell lymphoma: report of the 11th annual conference of the European Mantle Cell Lymphoma Network. <i>Leukemia and Lymphoma</i> , 2013, 54, 699-707.	0.6	37
74	Radiation Therapy in Primary Mediastinal B-Cell Lymphoma With Positron Emission Tomography Positivity After Rituximab Chemotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 87, 311-316.	0.4	35
75	Intensification of salvage treatment with high-dose sequential chemotherapy improves the outcome of patients with refractory or relapsed aggressive non-Hodgkin's lymphoma. <i>British Journal of Haematology</i> , 2001, 114, 333-341.	1.2	34
76	A Large-Scale Study of Bone Marrow Involvement in Patients with Hodgkin's Lymphoma. <i>Clinical Lymphoma and Myeloma</i> , 2004, 5, 50-55.	2.1	34
77	A phase II study on the role of gemcitabine plus romidepsin (GEMRO regimen) in the treatment of relapsed/refractory peripheral T-cell lymphoma patients. <i>Journal of Hematology and Oncology</i> , 2016, 9, 38.	6.9	34
78	Prognostic impact of somatic mutations in diffuse large B-cell lymphoma and relationship to cell-of-origin: data from the phase III GOYA study. <i>Haematologica</i> , 2020, 105, 2298-2307.	1.7	34
79	<sc>SIE</sc>, <sc>SIES</sc>, <sc>GITMO</sc> revised guidelines for the management of follicular lymphoma. <i>American Journal of Hematology</i> , 2013, 88, 185-192.	2.0	32
80	Core binding factor acute myeloid leukaemia and c-KIT mutations. <i>Oncology Reports</i> , 2013, 29, 1867-1872.	1.2	32
81	Italian Society of Hematology, Italian Society of Experimental Hematology, and Italian Group for Bone Marrow Transplantation Guidelines for the Management of Indolent, Nonfollicular B-Cell Lymphoma (Marginal Zone, Lymphoplasmacytic, and Small Lymphocytic Lymphoma). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 75-85.	0.2	32
82	Safety and efficacy of ⁹⁰<sc>Y</sc>ttriumâ€<sc>I</sc>britumomabâ€<sc>T</sc>iuxetan for untreated follicular lymphoma patients. An <sc>I</sc>talian cooperative study. <i>British Journal of Haematology</i> , 2014, 164, 710-716.	1.2	31
83	High dose sequential chemotherapy with autologous transplantation versus dose-dense chemotherapy MegaCEOP as first line treatment in poor-prognosis diffuse large cell lymphoma: an "Intergruppo Italiano Linfomi" randomized trial. <i>Haematologica</i> , 2005, 90, 793-801.	1.7	31
84	The host genetic background of DNA repair mechanisms is an independent predictor of survival in diffuse large B-cell lymphoma. <i>Blood</i> , 2011, 117, 2405-2413.	0.6	30
85	Diffuse Large B-cell Lymphoma in the elderly: standard treatment and new perspectives. <i>Expert Review of Hematology</i> , 2017, 10, 289-297.	1.0	30
86	Management of nodal indolent (non marginal-zone) non-Hodgkin's lymphomas: practice guidelines from the Italian Society of Hematology, Italian Society of Experimental Hematology and Italian Group for Bone Marrow Transplantation. <i>Haematologica</i> , 2005, 90, 1236-57.	1.7	30
87	Management of nodal diffuse large B-cell lymphomas: practice guidelines from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. <i>Haematologica</i> , 2006, 91, 96-103.	1.7	30
88	Update on the molecular pathogenesis and clinical treatment of mantle cell lymphoma: report of the 10th annual conference of the European Mantle Cell Lymphoma Network. <i>Leukemia and Lymphoma</i> , 2011, 52, 2226-2236.	0.6	29
89	Reduced intensity <sc>VEPEMB</sc> regimen compared with standard <sc>ABVD</sc> in elderly Hodgkin lymphoma patients: results from a randomized trial on behalf of the Fondazione Italiana Linfomi (<sc>FIL</sc>). <i>British Journal of Haematology</i> , 2016, 172, 879-888.	1.2	29
90	Lenalidomide maintenance after autologous haematopoietic stem-cell transplantation in mantle cell lymphoma: results of a Fondazione Italiana Linfomi (FIL) multicentre, randomised, phase 3 trial. <i>Lancet Haematology</i> , 2021, 8, e34-e44.	2.2	29

#	ARTICLE	IF	CITATIONS
91	Oxaliplatin-based chemotherapy (dexamethasone, high-dose cytarabine, and oxaliplatin) ± rituximab is an effective salvage regimen in patients with relapsed or refractory lymphoma. <i>Cancer</i> , 2010, 116, 4573-4579.	2.0	28
92	Khorana score and histotype predicts incidence of early venous thromboembolism in non-Hodgkin lymphomas. <i>Thrombosis and Haemostasis</i> , 2017, 117, 1615-1621.	1.8	27
93	Integrating novel drugs to chemoimmunotherapy in diffuse large B-cell lymphoma. <i>Expert Review of Hematology</i> , 2017, 10, 697-705.	1.0	26
94	The Role of Anthracyclines in Combination Chemotherapy for the Treatment of Follicular Lymphoma: Retrospective Study of the Intergruppo Italiano Linfomi 761 Cases. <i>Leukemia and Lymphoma</i> , 2003, 44, 1911-1917.	0.6	24
95	Fludarabine, Cyclophosphamide, and Rituximab in Salvage Therapy of Waldenström's Macroglobulinemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2013, 13, 231-234.	0.2	24
96	Lenalidomide monotherapy in heavily pretreated patients with non-Hodgkin lymphoma: an Italian observational multicenter retrospective study in daily clinical practice. <i>Leukemia and Lymphoma</i> , 2015, 56, 1671-1676.	0.6	22
97	CNS relapse in patients with DLBCL treated with lenalidomide plus R-CHOP (R2CHOP): analysis from two phase 2 studies. <i>Blood Cancer Journal</i> , 2018, 8, 63.	2.8	22
98	Fludarabine, cyclophosphamide, and rituximab in patients with advanced, untreated, indolent B-cell nonfollicular lymphomas. <i>Cancer</i> , 2012, 118, 3954-3961.	2.0	21
99	A B-cell receptor-related gene signature predicts survival in mantle cell lymphoma: results from the Fondazione Italiana Linfomi MCL-0208 trial. <i>Haematologica</i> , 2018, 103, 849-856.	1.7	21
100	End-of-treatment PET/CT predicts PFS and OS in DLBCL after first-line treatment: results from GOYA. <i>Blood Advances</i> , 2021, 5, 1283-1290.	2.5	21
101	Baseline PET-Derived Metabolic Tumor Volume Metrics Predict Progression-Free and Overall Survival in DLBCL after First-Line Treatment: Results from the Phase 3 GOYA Study. <i>Blood</i> , 2017, 130, 824-824.	0.6	21
102	Predictive value of the early response to chemotherapy in high-risk stages II and III Hodgkin's disease. <i>Cancer</i> , 1987, 60, 1713-1719.	2.0	20
103	The 68 Ge phantom-based FDG-PET site qualification program for clinical trials adopted by FIL (Italian) Tj ETQq1 1 0,784314 rgBT /Ove 0,4 20		
104	Prognostic Role of Pre-Radiation Therapy 18F-Fluorodeoxyglucose Positron Emission Tomography for Primary Mediastinal B-Cell Lymphomas Treated with R-CHOP or R-CHOP-Like Chemotherapy Plus Radiation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 95, 1239-1243.	0.4	20
105	PBSC mobilization in lymphoma patients: analysis of risk factors for collection failure and development of a predictive score based on the kinetics of circulating CD34+ cells and WBC after chemotherapy and G-CSF mobilization. <i>Hematological Oncology</i> , 2015, 33, 125-132.	0.8	19
106	Potential Benefit of Involved-Field Radiotherapy for Patients With Relapsed-Refractory Hodgkin's Lymphoma With Incomplete Response Before Autologous Stem Cell Transplantation. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, 14-22.	0.2	19
107	Rituximab Dose-Dense Chemotherapy Followed by Intensified High-Dose Chemotherapy and Autologous Stem Cell Transplantation (HDC+ASCT) Significantly Reduces the Risk of Progression Compared to Standard Rituximab Dose-Dense Chemotherapy As First Line Treatment in Young Patients with High-Risk (aa-IP1 2-3) Diffuse Large B-Cell Lymphoma (DLBCL): Final Results of Phase III Randomized Trial DLCL04 of the Fondazione Italiana Linfomi (FIL). <i>Blood</i> , 2012, 120, 688-688.	0.6	19
108	Prognostic impact of TP53 mutation in newly diagnosed diffuse large B-cell lymphoma patients treated in the FIL-DLCL04 trial. <i>British Journal of Haematology</i> , 2022, 196, 1184-1193.	1.2	19

#	ARTICLE	IF	CITATIONS
109	MACOP-B treatment for advanced stage diffuse large cell lymphoma: A multicenter Italian study. <i>European Journal of Cancer & Clinical Oncology</i> , 1989, 25, 1441-1449.	0.9	18
110	Safety and Efficacy of Single-Agent Bendamustine After Failure of Brentuximab Vedotin in Patients With Relapsed or Refractory Hodgkin's Lymphoma: Experience With 27 Patients. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 404-408.	0.2	18
111	The more patients you treat, the more you cure: managing cardiotoxicity in the treatment of aggressive non-Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2015, 56, 12-25.	0.6	18
112	Post-remissional and pre-transplant role of minimal residual disease detected by WT1 in acute myeloid leukemia: A retrospective cohort study. <i>Leukemia Research</i> , 2017, 61, 10-17.	0.4	18
113	Improved outcome of patients with relapsed/refractory Hodgkin lymphoma with a new fotemustine-based high-dose chemotherapy regimen. <i>British Journal of Haematology</i> , 2016, 172, 111-121.	1.2	16
114	Impact of bone marrow biopsy on response assessment in immunochemotherapy-treated lymphoma patients in GALLIUM and GOYA. <i>Blood Advances</i> , 2020, 4, 1589-1593.	2.5	16
115	High-grade B-cell lymphoma: how to diagnose and treat. <i>Expert Review of Hematology</i> , 2019, 12, 497-506.	1.0	15
116	Nonpegylated liposomal doxorubicin combination regimen (COMP) for the treatment of lymphoma patients with advanced age or cardiac comorbidity. <i>Hematological Oncology</i> , 2020, 38, 478-486.	0.8	15
117	Recurrence of Bcl-2/IgH polymerase chain reaction positivity following a prolonged molecular remission can be unrelated to the original follicular lymphoma clone. <i>Experimental Hematology</i> , 2003, 31, 784-788.	0.2	13
118	The efficacy and safety of bortezomib and dexamethasone as a maintenance therapy in patients with advanced multiple myeloma who are responsive to salvage bortezomib-containing regimens. <i>Cancer</i> , 2011, 117, 1884-1890.	2.0	13
119	Overview of alemtuzumab therapy for the treatment of T-cell lymphomas. <i>Leukemia and Lymphoma</i> , 2012, 53, 789-795.	0.6	13
120	Brentuximab Vedotin in CD30-Positive Lymphomas: A SIE, SIES, and GITMO Position Paper. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 507-513.	0.2	13
121	FOLLICULAR LYMPHOMA: THE MANAGEMENT OF ELDERLY PATIENT. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2016, 9, e2017009.	0.5	13
122	Lenalidomide in Diffuse Large B-Cell Lymphomas. <i>Advances in Hematology</i> , 2012, 2012, 1-5.	0.6	12
123	Perception of hepatitis B virus infection reactivation-related issues among specialists managing hematologic malignancies: result of an Italian survey. <i>Leukemia and Lymphoma</i> , 2014, 55, 2564-2571.	0.6	12
124	Impact of the type of anthracycline and of stem cell transplantation in younger patients with acute myeloid leukaemia: Long-term follow up of a phase III study. <i>American Journal of Hematology</i> , 2020, 95, 749-758.	2.0	12
125	State-of-the-art Therapy for Advanced-stage Diffuse Large B-cell Lymphoma. <i>Hematology/Oncology Clinics of North America</i> , 2016, 30, 1147-1162.	0.9	11
126	Single-agent panobinostat for relapsed/refractory diffuse large B-cell lymphoma: clinical outcome and correlation with genomic data. A phase 2 study of the Fondazione Italiana Linfomi. <i>Leukemia and Lymphoma</i> , 2018, 59, 2904-2910.	0.6	11

#	ARTICLE	IF	CITATIONS
127	Variable global distribution of cell-of-origin from the ROBUST phase III study in diffuse large B-cell lymphoma. <i>Haematologica</i> , 2020, 105, e72-e75.	1.7	11
128	The classic prognostic factors in advanced Hodgkin's lymphoma patients are losing their meaning at the time of Pet-guided treatments. <i>Annals of Hematology</i> , 2020, 99, 277-282.	0.8	11
129	Dual targeting of the DNA damage response pathway and BCL-2 in diffuse large B-cell lymphoma. <i>Leukemia</i> , 2022, 36, 197-209.	3.3	11
130	Most immunoglobulin heavy chain switch mu rearrangements in B-cell chronic lymphocytic leukemia are internal deletions. <i>FEBS Letters</i> , 2002, 518, 119-123.	1.3	10
131	Management of relapsed/refractory mantle cell lymphoma: a review of current therapeutic strategies. <i>Leukemia and Lymphoma</i> , 2014, 55, 988-998.	0.6	10
132	Genomic alterations of ribosomal protein genes in diffuse large B cell lymphoma. <i>British Journal of Haematology</i> , 2019, 185, 330-334.	1.2	10
133	Single-nucleotide Fcγ3 receptor polymorphisms do not impact obinutuzumab/rituximab outcome in patients with lymphoma. <i>Blood Advances</i> , 2021, 5, 2935-2944.	2.5	10
134	Final Analysis of GOYA: A Randomized, Open-Label, Phase III Study of Obinutuzumab or Rituximab Plus CHOP in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2019, 134, 4088-4088.	0.6	10
135	Are We Ready to Treat Diffuse Large B-cell and High-Grade Lymphoma According to Major Genetic Subtypes?. <i>HemaSphere</i> , 2019, 3, e284.	1.2	9
136	Persistent mediastinal FDG uptake on PET-CT after frontline therapy for Hodgkin lymphoma: biopsy, treat or observe?. <i>Leukemia and Lymphoma</i> , 2020, 61, 318-327.	0.6	9
137	Thymic function and immunoglobulin mutation genotype in B-cell chronic lymphocytic leukemia patients. <i>International Journal of Cancer</i> , 2003, 107, 958-961.	2.3	8
138	A three-gene signature based on MYC, BCL-2 and NFKB1A improves risk stratification in diffuse large B-cell lymphoma. <i>Haematologica</i> , 2021, 106, 2405-2416.	1.7	8
139	BCL2 Expression in First-Line Diffuse Large B-Cell Lymphoma Identifies a Patient Population With Poor Prognosis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 267-278.e10.	0.2	8
140	Comprehensive Minimal Residual Disease (MRD) Analysis of the Fondazione Italiana Linfomi (FIL) MCL0208 Clinical Trial for Younger Patients with Mantle Cell Lymphoma: A Kinetic Model Ensures a More Refined Risk Stratification. <i>Blood</i> , 2018, 132, 920-920.	0.6	8
141	Safety and efficacy of ruxolitinib in myelofibrosis patients without splenomegaly. <i>British Journal of Haematology</i> , 2016, 174, 160-162.	1.2	7
142	G-CSF use in patients receiving first-line chemotherapy for non-Hodgkin's lymphoma (NHL) and granulocyte-colony-stimulating factors (G-CSF) as observed in clinical practice in Italy. <i>Medical Oncology</i> , 2016, 33, 139.	1.2	7
143	B-IGEV (bortezomib plus IGEV) versus IGEV before high-dose chemotherapy followed by autologous stem cell transplantation in relapsed or refractory Hodgkin lymphoma: a randomized, phase II trial of the Fondazione Italiana Linfomi (FIL). <i>Leukemia and Lymphoma</i> , 2016, 57, 2375-2381.	0.6	7
144	Ruxolitinib in elderly patients with myelofibrosis: impact of age and genotype. A multicentre study on 291 elderly patients. <i>British Journal of Haematology</i> , 2018, 183, 35-46.	1.2	7

#	ARTICLE	IF	CITATIONS
145	Aggressive Non-Hodgkin lymphomas: risk factors and treatment of central nervous system recurrence. Expert Review of Hematology, 2019, 12, 787-796.	1.0	7
146	Prognostic significance of FCGR2B expression for the response of DLBCL patients to rituximab or obinutuzumab treatment. Blood Advances, 2021, 5, 2945-2957.	2.5	7
147	Prevention of invasive fungal infections in patients with acute myeloid leukaemia: results of a single centre retrospective observational study with the use of posaconazole versus conventional mould-active azoles. Journal of Chemotherapy, 2014, 26, 315-320.	0.7	6
148	The efficacy of lenalidomide combination therapy in heavily pretreated non-Hodgkin lymphoma patients: an Italian observational, multicenter, retrospective study. Leukemia and Lymphoma, 2017, 58, 226-229.	0.6	6
149	Bcl-2 inhibition in DLBCL: the times they are a-changing?. Blood, 2021, 137, 577-579.	0.6	6
150	Targeted locus amplification to detect molecular markers in mantle cell and follicular lymphoma. Hematological Oncology, 2021, 39, 293-303.	0.8	6
151	A prognostic model integrating PET-derived metrics and image texture analyses with clinical risk factors from GOYA. EJHaem, 2022, 3, 406-414.	0.4	6
152	A Clinical Prognostic Model Based on Machine Learning from the Fondazione Italiana Linfomi (FIL) MCL0208 Phase III Trial. Cancers, 2022, 14, 188.	1.7	6
153	Consensus conference on the use of 90Yttrium-ibritumomab tiuxetan therapy in clinical practice. A project of the Italian Society of Hematology. American Journal of Hematology, 2010, 85, 147-155.	2.0	5
154	Update in Indolent Non-Hodgkin Lymphoma (NHL): Paradigm for Waldenström's Macroglobulinemia (WM). Clinical Lymphoma, Myeloma and Leukemia, 2011, 11, 149-151.	0.2	5
155	Primary Diffuse Large B-Cell Lymphoma of the Testis (PTL): A Prospective Study of Rituximab (R)-CHOP with CNS and Contralateral Testis Prophylaxis. Results of the IELSG 10 Study.. Blood, 2006, 108, 208-208.	0.6	5
156	Follicular origin of a subset of CD5+ diffuse large B-cell lymphomas. American Journal of Clinical Pathology, 2005, 124, 182-90.	0.4	5
157	Allogeneic stem cell transplant for adults with myelodysplastic syndromes: relevance of pre-transplant disease status. Leukemia and Lymphoma, 2014, 55, 863-869.	0.6	4
158	Recent advances in clinical studies and the evolving role of subtyping for patients with diffuse large B-cell lymphoma. Future Oncology, 2017, 13, 859-862.	1.1	4
159	Current options to manage Waldenström's macroglobulinemia. Expert Review of Hematology, 2017, 10, 637-647.	1.0	4
160	Yttrium-90 ibritumomab tiuxetan (Zevalin) followed by BEAM (Z-BEAM) conditioning regimen and autologous stem cell transplantation (ASCT) in relapsed or refractory high-risk B-cell non-Hodgkin lymphoma (NHL): a single institution Italian experience. Annals of Hematology, 2018, 97, 1619-1626.	0.8	4
161	Salvage regimens for Hodgkin's lymphoma in the brentuximab vedotin era. Lancet Oncology, The, 2018, 19, 162-163.	5.1	4
162	Diffuse large B cell lymphoma cell of origin by digital expression profiling in the REAL Phase 1&2 study. British Journal of Haematology, 2018, 182, 453-456.	1.2	4

#	ARTICLE	IF	CITATIONS
163	A brief rituximab, bendamustine, mitoxantrone (RÊledRBM) induction followed by rituximab consolidation in elderly patients with advanced follicular lymphoma: a phase II study by the Fondazione Italiana Linfomi (FIL). British Journal of Haematology, 2021, 193, 280-289.	1.2	4
164	Outcomes of older patients with follicular lymphoma using individual data from 5922 patients in 18 randomized controlled trials. Blood Advances, 2021, 5, 1737-1745.	2.5	4
165	Radioimmunotherapy (RIT) with 90Y-Ibritumomab Tiuxetan (Zevalin) for the Treatment of Relapsed or Resistant Aggressive Diffuse Large B-Cell Lymphoma (DLBCL) Heavily Pretreated with Rituximab + Chemotherapy: A GIMURELL Experience.. Blood, 2007, 110, 4478-4478.	0.6	4
166	Brief Chemoimmunotherapy R-FND with Rituximab Consolidation Followed by Randomization Between Rituximab Maintenance Vs. Observation As First Line Treatment in Elderly Patients with Advanced Follicular Lymphoma (FL): Final Results of a Prospective Randomized Trial by Italian Lymphoma Foundation (FIL). Blood, 2011, 118, 777-777.	0.6	4
167	Baseline Total Metabolic Tumor Volume is Prognostic for Refractoriness to Immunochemotherapy in DLBCL: Results From GOYA. Clinical Lymphoma, Myeloma and Leukemia, 2022, 22, e804-e814.	0.2	4
168	The identification of TCF1+ progenitor exhausted T cells in THRLBCL may predict a better response to PD-1/PD-L1 blockade. Blood Advances, 2022, 6, 4634-4644.	2.5	4
169	A retrospective study of RÊledRHAP/Ox for early progressing follicular lymphoma. British Journal of Haematology, 2018, 183, 828-831.	1.2	3
170	Upfront intensive chemo-immunotherapy with autograft in 199 adult mantle cell lymphoma patients: prolonged survival and cure potentiality at long term. Bone Marrow Transplantation, 2021, 56, 2606-2609.	1.3	3
171	Salvage Treatment with Lenalidomide and Dexamethasone In Patients with Relapsed Refractory Mantle Cell Lymphoma: Clinical Results and Modifications of Angiogenic Biomarkers. Blood, 2010, 116, 966-966.	0.6	3
172	Pharmacokinetics of Obinutuzumab (GA101) in Patients with CD20+ Relapsed/Refractory Malignant Disease Receiving Concomitant Chemotherapy (Phase Ib Study BO21000),. Blood, 2011, 118, 3704-3704.	0.6	3
173	Safety and efficacy of atezolizumab with obinutuzumab and bendamustine in previously untreated follicular lymphoma. Blood Advances, 2022, 6, 5659-5667.	2.5	3
174	Front-line therapy for nonlocalized diffuse large B-cell lymphoma: what has been demonstrated and what is yet to be established. Future Oncology, 2008, 4, 199-210.	1.1	2
175	XVI. CNS prophylaxis in aggressive lymphomas: for whom and how. Hematological Oncology, 2013, 31, 89-91.	0.8	2
176	Alternative options for elderly patients with limited stage diffuse large B-cell lymphoma: R-chemotherapy vs. R-chemotherapy plus radiotherapy. Leukemia and Lymphoma, 2016, 57, 2677-2680.	0.6	2
177	Chemotherapy combinations for B-cell lymphoma and chemo-free approach in elderly patients: an update on best practice. Expert Review of Hematology, 2020, 13, 851-869.	1.0	2
178	Rituximab as Adjuvant to Dose-Dense and High Dose Chemotherapy (HDC) with Autologous Stem Cell Transplantation (ASCT) as First Line Treatment in Stage IIIÊledRIV Diffuse Large B-Cell Lymphoma (DLBCL) at Poor Prognosis: Final Analysis of Phase II GIMURELL Trial.. Blood, 2006, 108, 329-329.	0.6	2
179	Role of Positron Emission Tomography (PET/CT) in Primary Mediastinal Large B Cell Lymphoma (PMLBCL): Preliminary Results of an International Phase II Trial (IELSG-26 Study) Conducted On Behalf of the International Extranodal Lymphoma Study Group (IELSG), the Fondazione Italiana Linfomi (FIL) and the UK NCRI Lymphoma Group. Blood, 2012, 120, 1566-1566.	0.6	2
180	Long term outcome of localized aggressive non-Hodgkin lymphoma treated with a short weekly chemotherapy regimen (doxorubicin, cyclophosphamide, bleomycin, vincristine, and prednisone) and involved field radiotherapy: result of a Gruppo Italiano Multiregionale per lo Studio dei Linfomi e Leucemie (GIMURELL) study. Leukemia and Lymphoma, 2009, 50, 1475-1481.	0.6	1

#	ARTICLE	IF	CITATIONS
181	The risk of CNS involvement in aggressive lymphomas in the rituximab era. Expert Review of Hematology, 2013, 6, 643-652.	1.0	1
182	Lenalidomide in the Treatment of Lymphoproliferative Disorders and Multiple Myeloma. Advances in Hematology, 2013, 2013, 1-2.	0.6	1
183	Role of Chemotherapy and Allografting in the Treatment of Acute Lymphoblastic Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2016, 16, 96-103.	0.2	1
184	Rituximab and autologous stem-cell transplantation for high-risk diffuse large B-cell lymphoma "Authors' reply. Lancet Oncology, The, 2017, 18, e558.	5.1	1
185	Histological transformation and secondary malignancies in follicular lymphoma. Lancet Haematology,the, 2018, 5, e496-e497.	2.2	1
186	Brentuximab vedotin-based salvage treatment in Hodgkin's lymphoma. Lancet Oncology, The, 2018, 19, 1144-1146.	5.1	1
187	Monoclonal antibody-drug conjugates in B-cell lymphomas. Lancet Haematology,the, 2019, 6, e232-e233.	2.2	1
188	Partial responses to ibrutinib in Waldenström macroglobulinaemia "good enough?. British Journal of Haematology, 2021, 192, 423-424.	1.2	1
189	Brief Chemoimmunotherapy Rituximab (R)-FND ± R Maintenance as First Line Treatment in Elderly Patients with Advanced Follicular Lymphoma (FL): Preliminary Analysis of a Prospective Randomized III Trial. Blood, 2008, 112, 834-834.	0.6	1
190	PET-CR as a potential surrogate endpoint in untreated DLBCL: meta-analysis and implications for clinical trial design. Leukemia and Lymphoma, 0, , 1-16.	0.6	1
191	Evaluation of the effect of prospective biomarker testing on progression-free survival in diffuse large B-cell lymphoma. Leukemia and Lymphoma, 2021, 62, 999-1002.	0.6	0
192	Antibody Therapies for Large B-Cell Lymphoma. Biologics: Targets and Therapy, 2021, Volume 15, 153-174.	3.0	0
193	Frontline chemotherapy-free induction for mantle cell lymphoma. Lancet Oncology, The, 2022, , .	5.1	0